Search Results
Your search for A matches 32887 pages
Showing 18651 - 18700Association of Event-Free Survival at 24 Months With Overall Survival in Peripheral T-Cell Lymphoma
In a study reported in the Journal of Clinical Oncology, Maurer et al found that event-free survival at 24 months (EFS24) was associated with prolonged subsequent overall survival among patients with peripheral T-cell lymphoma (PTCL). Study Details The study involved patients with systemic PTCL...
Combination Therapy for Advanced Lung and Thymus Carcinoids
A European phase II trial has shown activity of long-acting pasireotide, everolimus (Afinitor), or their combination in patients with advanced lung and thymus carcinoids. These study findings were reported by Ferolla et al in The Lancet Oncology. Study Details In the study, 124 patients from 36...
FDA Approves Brentuximab Vedotin for Primary Cutaneous Anaplastic Large Cell Lymphoma
Today, the U.S. Food and Drug Administration (FDA) granted regular approval to brentuximab vedotin (Adcetris) for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides who have received prior systemic therapy. ALCANZA...
FDA Approves Letermovir for Prophylaxis of Cytomegalovirus Infection and Disease in Allogeneic Stem Cell Transplant Patients
Today, the U.S. Food and Drug Administration (FDA) approved letermovir (Prevymis) once-daily tablets for oral use and injection for intravenous infusion. Letermovir is indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogeneic...
ARIEL3 Investigators Clarify the Effects of Rucaparib on the Liver
PRIMARY RESULTS from the randomized, placebo-controlled, phase III study ARIEL3—presented at the European Society for Medical Oncology (ESMO) 2017 Congress and published recently in The Lancet1—demonstrated that maintenance treatment with the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib ...
Predisposition to Breast Cancer due to Mutations Other Than BRCA1/BRCA2 in Ashkenazi Jewish Women
A cohort study in Ashkenazi Jewish women with breast cancer identified mutations other than BRCA1 and BRCA2 founder alleles that were associated with cancer risk. These results were reported by Walsh et al in JAMA Oncology. Among Ashkenazi Jewish women, three mutations in BRCA1 and BRCA2...
Ovarian Function Recovery During Anastrozole Therapy in Postmenopausal Patients With Breast Cancer
In the phase III DATA trial reported in the Journal of the National Cancer Institute by Vivianne C.G. Tjan-Heijnen, MD, PhD, of the Maastricht University Medical Centre, the Netherlands, and colleagues, 12% of women with breast cancer who had chemotherapy-induced ovarian function failure...
10-Year Follow-up on Adjuvant Therapy in Postmenopausal Early Breast Cancer
The 10-year follow-up of the phase III TEAM trial has shown that exemestane alone and sequential tamoxifen/exemestane provide similar outcomes as adjuvant endocrine therapy in postmenopausal women with hormone receptor–positive early breast cancer. The findings were reported in The Lancet Oncology ...
BRCA1/2 Status in Response to Therapy in Triple-Negative Breast Cancer
An analysis of the GeparSixto trial in triple-negative breast cancer showed that adding carboplatin to neoadjuvant therapy improved pathologic complete response rate in patients without BRCA1/2 mutation and that response rates were higher overall in those with mutations, without additive effects...
Paul Neiman, MD, PhD, Founding Member of Fred Hutch, Dies at 78
PAUL NEIMAN, MD, PhD, a founding member of Fred Hutchinson Cancer Research Center (Fred Hutch), transplant physician, and cancer biologist, died on October 11 of complications from pancreatic cancer. He was 78. Dr. Neiman was also one of the founders and leaders of the Basic Sciences Division,...
Life With Death in the Room
It began, as so many do, with what a doctor often calls “a small spot,” a vague description that makes a potentially fatal disease sound like something that, with a slight bit of attention, can be ridded, like erasing a misplaced comma. In 2015, during a routine mammogram, doctors found one “small ...
A Revolutionary Technology Offers Hope and Ethical Concern
Aldous Huxley’s classic 1932 dystopian novel Brave New World pictures an eerie future where humans are genetically bred, altered to create worthy citizens. Welcome back to the future. First there was the astounding feat of sequencing the entire human genome; now, thanks to a revolutionary...
Higher Risk of Breast Cancer Does Not Motivate Cancer Screening in Many Women
Some women, because of genetic predisposition, personal, or family history, have a higher-than-average lifetime risk of developing breast cancer. For those women, earlier magnetic resonance imaging (MRI) is recommended for cancer screening. But according to new findings presented at the American...
Association of Tumor HER3 Expression With Treatment Outcome in Advanced Colorectal Cancer
In a study reported in JAMA Oncology, Seligmann et al found that higher tumor HER3 messenger RNA expression among patients with RAS wild-type tumors was associated with a better outcome with panitumumab (Vectibix) plus irinotecan vs irinotecan alone among patients with advanced colorectal cancer in ...
Predictors of Posthospital Care Transitions in Advanced Cancer
In a study reported in the Journal of Clinical Oncology, Lage and colleagues found that among patients with advanced cancer who had an unplanned hospital admission, those discharged to hospice or post–acute care facilities had a worse symptom burden and physical function and worse survival...
Internal Radiotherapy vs Kinase Inhibitor in Advanced Hepatocellular Carcinoma
A French phase III trial has shown no significant survival difference between selective internal radiotherapy with yttrium-90 resin microspheres vs sorafenib (Nexavar) in patients with advanced hepatocellular carcinoma. The findings were reported by Vilgrain et al in The Lancet Oncology. Study...
Gerold Bepler, MD, PhD, Elected to Association of American Cancer Institute’s Board of Directors
GEROLD BEPLER, MD, PhD, President and Chief Executive Officer of the Barbara Ann Karmanos Cancer Institute, has been elected to serve a 3-year term on the Association of American Cancer Institutes (AACI) Board of Directors. AACI comprises 97 leading cancer research centers in North America and is...
New Cancer Care Collaboration Brings Memorial Sloan Kettering Cancer Care to Norwalk Hospital
NORWALK HOSPITAL and Memorial Sloan Kettering Cancer Center (MSK) announced a new cancer care collaboration that will integrate MSK medical and radiation oncologists and care practices with the existing cancer program at the C. Anthony and Jean Whittingham Cancer Center at Norwalk Hospital. For...
Barrie Cassileth, PhD: A Pioneer in Integrative Oncology
Integrative oncology is an evolving evidence-based specialty providing whole-person care by combining conventional approved cancer treatments with integrative and complementary therapies that best serve the needs of patients based on their diagnosis, prognosis, treatment history, and individual...
National Cancer Institute Awards Dr. Ruth Etzioni 5-Year Grant to Fill Gaps in Cancer-Recurrence Data
RUTH ETZIONI, PhD, a Biostatistician at Fred Hutchinson Cancer Research Center’s Public Health Sciences Division, has received a 5–year National Institutes of Health grant to advance the science of cancer surveillance by developing, validating, and deploying a scalable and automated approach for...
Two Individuals Recognized With NCCS Ellen L. Stovall Award
THE NATIONAL COALITION FOR CANCER SURVIVORSHIP (NCCS) presented its second annual Ellen L. Stovall Award for Innovation in Patient-Centered Cancer Care recently in Washington, DC. This year’s award recipients were Pat Coyne, MSN, of the Medical University of South Carolina, and Meg Gaines, JD, of...
Clinical Trials Actively Recruiting Patients With Lung Cancer
THE INFORMATION contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies focused on patients with lung cancer. These studies highlight combinations of chemotherapy, mutation-specific treatments, stereotactic body radiation therapy, metastatic control, cancer...
Fox Chase Cancer Center Receives Historic Gift to Establish Pancreatic Cancer Institute
PHILADELPHIA PHILANTHROPIST Concetta “Chet” Greenberg has made a transformational gift to create The Marvin and Concetta Greenberg Pancreatic Cancer Institute at Fox Chase Cancer Center. This multimillion-dollar commitment will significantly accelerate the pace of pancreatic cancer research, and...
UCLA Researchers Awarded $1M Grant to Advance Prostate Cancer Research
UNIVERSITY OF CALIFORNIA at Los Angeles (UCLA) researchers Johannes Czernin, MD, and Caius Radu, MD, have been awarded a 2017 Challenge Award from the Prostate Cancer Foundation to fund their preclinical studies and clinical trials testing the efficacy of 177-Lu-PSMA-617, a novel radiation-emitting ...
FDA Approves Intravenous Rolapitant for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting
ON OCTOBER 25, the U.S. Food and Drug Administration (FDA) approved intravenous (IV) rolapitant (Varubi) in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including...
Balancing Immune-Related Adverse Events With Efficacy of Dual Checkpoint Inhibitor Therapy in Melanoma
MUCH PROGRESS has been made in the past decade in the treatment of patients with newly diagnosed metastatic melanoma. In the front-line setting, programmed cell death protein 1 (PD-1) monotherapy (nivolumab [Opdivo] and pembrolizumab [Keytruda]) and combined PD-1 plus cytotoxic...
Long-Term Survival Rates More Than Double Previous Estimates for Locally Advanced Lung Cancer
THE LONG-TERM RESULTS of a phase III clinical trial indicate that survival rates for patients receiving chemoradiation for unresectable, locally advanced non–small cell lung cancer (NSCLC) may be more than twice as high as previous estimates, setting a new benchmark of survival for patients with...
EXPERT POINT OF VIEW: Geraldine M. Jacobson, MD, MPH, MBA
GERALDINE M. JACOBSON, MD, MPH, MBA, ASTRO Secretary/Treasurer, Professor and Chair of Radiation Oncology at the West Virginia University School of Medicine, Morgantown, went into more detail about the importance of this study. “The study directly compared brachytherapy/chemotherapy, which we use...
Pelvic Radiation Therapy Preferred Over Brachytherapy Plus Chemotherapy in Treatment of High-Risk Endometrial Cancer
VAGINAL CUFF BRACHYTHERAPY plus chemotherapy failed to show superiority over pelvic radiation therapy for women with high-risk stage I–II endometrial cancer in a phase III trial.1 Furthermore, vaginal cuff brachytherapy plus chemotherapy led to more pelvic and para-aortic nodal recurrences and...
Study Finds More Patients Treated for and Surviving Early-Stage NSCLC
WITH THE ADVANCEMENT of surgical and radiation therapy strategies for stage I non–small cell lung cancer (NSCLC), more patients are being treated, resulting in higher survival rates, according to a study published online in The Annals of Thoracic Surgery.1 “More and more patients are being cured...
Dacomitinib vs Gefitinib in Advanced NSCLC: Improving Upon Established First-Line Targeted Therapy
THE RESULTS FROM the ARCHER 1050 study—reported by Wu et al1 and reviewed in this issue of The ASCO Post—highlight the recent optimism about improved outcomes in metastatic non–small cell lung cancer (NSCLC) harboring mutations in the epidermal growth factor receptor (EGFR) gene. This trial...
Dacomitinib Prolongs Progression-Free Survival vs Gefitinib in First-Line Treatment of EGFR-Mutant NSCLC
THE PHASE III ARCHER 1050 trial has shown superior progression-free survival with the second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor dacomitinib vs gefitinib (Iressa) in the first-line treatment of advanced EGFR-mutant non–small-cell lung cancer...
New Editor-in-Chief Named to Annals of Surgical Oncology
THE SOCIETY OF SURGICAL ONCOLOGY has announced Kelly M. McMasters, MD, PhD, will assume the role of Editor-in-Chief of Annals of Surgical Oncology, effective March 2018. Dr. McMasters will oversee the print and online editions of the journal and, with Mark Roh, MD, Executive Editor, will lead the...
National Academy of Medicine Elects 80 New Members
THE NATIONAL ACADEMY OF MEDICINE announced the election of 70 regular members and 10 international members during its annual meeting in October. Election to the Academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated...
Characteristics of Recurrence in Stage I to III Midgut Neuroendocrine Tumors
In a study reported in the Journal of the National Cancer Institute, Cives et al found that postsurgical relapse occurred in 31% of patients with stage I to III midgut neuroendocrine tumors over long-term follow-up, with liver, mesentery, and pelvic lymph nodes being the main sites of relapse....
HSD3B1 Variant and Response to Nonsteroidal CYP17A1 Inhibition in Castration-Resistant Prostate Cancer
As reported in JAMA Oncology by Almassi et al, extragonadal androgen ablation with the nonsteroidal CYP17A1 inhibitor ketoconazole improved outcome in men with metastatic castration-resistant prostate cancer according to the number of inherited HSD3B1 (1245C) alleles. HSD3B1 (1245C) is associated...
ASCO Cites Evidence That Alcohol Is Linked to Cancer, Calls for Reduced Alcohol Consumption
Alcohol use—whether light, moderate, or heavy—is linked with increasing the risk of several leading cancers, including those of the breast, colon, esophagus, and head and neck, according to evidence gathered by ASCO. In a statement released November 7 identifying alcohol as a definite...
Long-Term Follow-up of Cardiac Function After Adjuvant Therapy With Trastuzumab in Early Breast Cancer
As reported by Ganz et al in the Journal of Clinical Oncology, long-term follow-up of patients in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-31/NRG Oncology trial showed no worsening of cardiac function or quality of life with the addition of adjuvant trastuzumab...
Jenske Geerling, NP, on Painful Bone Metastases: Study Results on Nurse-Led Pain Education
Jenske Geerling, NP, of the University Medical Center Groningen, discusses findings from a multicenter trial on patient education, pain reduction, and quality of life (Abstract 203).
FDA Approves Alectinib for ALK-Positive Metastatic NSCLC
On November 6, 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to alectinib (Alecensa) for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non–small cell lung cancer (NSCLC), as detected by an FDA-approved test. In December 2015,...
FDA Approves Vemurafenib for Certain Patients With Erdheim-Chester Disease
On November 6, the U.S. Food and Drug Administration (FDA) expanded the approval of vemurafenib (Zelboraf) to include the treatment of certain adult patients with Erdheim-Chester disease (ECD), a rare cancer of the blood. Vemurafenib is indicated to treat patients whose cancer cells have a specific ...
FDA Accepts sBLA for Bevacizumab as a Front-Line Treatment for Advanced Ovarian Cancer
On October 25, Genentech announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for bevacizumab (Avastin) in combination with chemotherapy (carboplatin and paclitaxel), followed by bevacizumab alone, for the front-line ...
Hospital Emergency Department Practices for Treating Older Adults With Cancer
A new study published by Lipitz-Snyderman et al in JNCCN–Journal of the National Comprehensive Cancer Network found that among patients presenting to the emergency department, those with cancer, especially those aged 75 years or older, are more likely to be admitted to the hospital—and...
Fat Cells May Inactivate Chemotherapeutic Drug and Contribute to Poorer Survival in ALL
It is well established that obesity increases the risk for cancer mortality, although no mechanisms have been proven to explain the reason for this association. Now a laboratory study investigating how obesity might alter the effectiveness of daunorubicin in the treatment of acute lymphoblastic...
Worldwide Cancer Incidence and Mortality Among Persons Aged 20 to 39 in 2012
In a study reported in The Lancet Oncology, Fidler et al found that cancer burden was higher worldwide among women vs men aged 20 to 39 in 2012 and that the incidence was higher but mortality lower in very high vs low Human Development Index regions. Study Details The study involved data from the ...
Novel Adverse Genomic Rearrangement Signature in High-Grade Serous Ovarian Cancer
As reported by Hillman et al in the Journal of the National Cancer Institute, a novel genomic rearrangement signature associated with poorer overall survival has been identified in high-grade serous ovarian cancer. Study Details In the study, clinical data and whole-genome sequencing results were ...
Combination Therapy for Advanced BRAF V600–Mutant Anaplastic Thyroid Cancer
A phase II study reported by Subbiah et al in the Journal of Clinical Oncology indicates activity of the combination of dabrafenib (Tafinlar) plus trametinib (Mekinist) in patients with locally advanced or metastatic BRAF V600–mutant anaplastic thyroid cancer. Study Details In the study,...
ASCO’s Patient Resources for Lung Cancer Awareness Month
Visit ASCO’s patient information website, Cancer.Net, for comprehensive guides to non–small cell lung cancer at www.cancer.net/nsclc and small cell lung cancer at www.cancer.net/sclc. A shorter, one-page fact sheet on lung cancer is also available, as well as specialized resources for caregiving,...
Fall Wrap-Up: Research Community Forum and 2017 ASCO Advocacy Summit
ASCO Research Community Forum The ASCO Research Community Forum (RCF) Annual Meeting was held September 24–25, with the theme of Advancing Cancer Care Through Research Partnerships. The RCF Annual Meeting brings together ASCO leaders, regulatory experts, physician investigators, and research staff...
Conqueror in Action: Six-Time Survivor Brittany Sullivan Takes on Sarcoma
Alveolar soft part sarcoma (ASPS) is a cancer so rare that some oncologists have never heard of it. Brittany Sullivan, a 29-year-old anatomy teacher from Nashville, Tennessee, learned about it when she was 3 years old. She has been conquering it ever since. Since her childhood diagnosis, Ms....
